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Analysis of fetal material gained by invasive 
procedures
The current gold standard for prenatal diagnosis for fetal 
aneuploidy is a full karyotype obtained from the culture 
of  amniocytes  or  chorionic  villus  cells,  which  are 
obtained by invasive procedures such as amniocentesis or 
chorionic  villus  sampling  (CVS)  [1-3].  It  is  unclear, 
however,  how  long  this  practice  will  remain  standard 
operating  procedure  because  the  classical  karyotype 
yields  a  limited  amount  of  information  by  today’s 
standards,  and  because  the  lengthy  culture  period  of 
typically  10  to  14  days  is  no  longer  acceptable  in  our 
high-speed society [1,2].
The most frequent severe chromosomal anomaly in live 
births is trisomy 21 (Down syndrome), and trisomies 13 
and  18  are  associated  with  intra-uterine  lethality. 
Strategies  have  evolved  to  detect  the  most  common 
anomalies rapidly following an invasive procedure. These 
include direct preparations of uncultured chorionic villus 
cells, multi-color fluorescent in situ hybridization (FISH) 
[4,5], quantitative fluorescent PCR (qf-PCR) [6,7], real-
time  quantitative  PCR  [8],  PCR  coupled  with  mass 
spectrometry  [9],  multiplex  ligation-dependent  probe 
ampli  fication,  and  most  recently  digital  PCR  [10,11]. 
Usually the FISH- or PCR-based tests offer information 
concerning the ploidy of chromosomes 13, 18, 21, X and 
Y, as these analyses should in theory cover about two-
thirds  of  the  chromosomal  anomalies  that  are  most 
commonly found at the time of amniocentesis and about 
85% of those found at the time of birth [12]. Both qf-PCR 
and  rapid  FISH  methods,  such  as  Fast-FISH,  enable 
informative results to be obtained in a matter of hours 
[4,6], so the expectant couple can be informed if the fetus 
is affected by Down syndrome or not within a very short 
time-frame, instead of having to wait for almost 2 weeks. 
The introduction of such services has been so successful 
that it has been suggested that they replace conventional 
karyotyping  completely,  as  a  cost-saving  measure  [12]. 
These rapid tests, however, provide only a limited amount 
of information, and large-scale studies conducted in the 
UK have shown that their sole use may lead to the failure 
to detect 30 to 45% of the fetal chromosomal anomalies 
occurring in the study population [13]. For this reason, 
conventional  G-banded  karyotyping  is  still  routinely 
performed on fetal material obtained by invasive means.
New  technologies  such  as  microarray  comparative 
genomic hybridization, also termed chromosomal micro-
array  (CMA),  enable  a  more  precise  assessment  of 
chromo  somal structure and have thus been proposed to 
be useful for prenatal diagnosis [1]. However, as it would 
be too costly to perform CMA and conventional G-banded 
karyotyping in parallel on the same sample, the question 
has been raised as to whether the former should replace 
the  latter  [1,14,15].  In  a  large-scale  meta-analysis  of  33 
studies involving over 21,000 patients performed by the 
International Standard Cytogenomic Assay Consortium, it 
was determined that CMA yielded a 15 to 20% higher 
diagnostic  yield  than  G-banded  karyotyping  for  the 
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or duplications [14]. Such alterations have been shown to 
be  involved  in  disorders  such  as  unexplained  develop-
ment  delay/intellectual  disability,  autism  spectrum  dis-
orders and multiple congenital anomalies.
Consequently, it seems that CMA would provide better 
value for money than the continued use of traditional G-
banded  karyotyping,  and  it  was  recommended  by  the 
International Standard Cytogenomic Assay Consortium 
that  it  should  be  considered  as  a  ‘first  tier’  option  for 
prenatal diagnosis [14]. Unfortunately, in this regard no 
consensus  has  yet  been  attained,  as  is  evident  by  the 
recent  Committee  Opinion  no.  446  released  by  the 
American  College  of  Obstetrics  and  Gynecology  [16], 
which states that CMA is currently not a suitable replace-
ment for classical cytogenetics in prenatal diagnosis. This 
is due to a perceived higher cost and apparent technical 
issues,  such  as  a  possible  inability  to  detect  balanced 
trans  locations or cases of triploidy by CMA. Given that 
several studies indicate, however, that array technologies 
may  under  certain  conditions  provide  more  detailed 
insight than classical G-banding with regard to chromo-
some rearrangements, it is possible that this issue will be 
resolved  in  future  as  CMA  techniques  become  more 
technically proficient, robust and widespread [14].
Non-invasive prenatal diagnosis of fetal 
aneuploidies: direct versus indirect approaches
As invasive practices such as CVS or amniocentesis carry 
an inherent risk of fetal injury and loss, several alternative 
approaches that would allow a non-invasive assessment 
of the fetal genotype have been explored [2,17]. Initial 
attempts  focused  on  the  enrichment  of  fetal  cells 
(erythro  blasts or trophoblasts) from maternal blood and 
the retrieval of trophoblast cells by transcervical lavage 
[18]. Despite almost three decades of intensive efforts, 
none  of  these  approaches  has  proven  to  be  ready  for 
clinical application. This may, however, change with the 
development  of  effictive  enrichment  devices  using 
microfluidics or automated scanning microscopy [2].
Consequently, most attention has been focused on the 
potential use of cell-free placentally derived nucleic acids 
[19]. In this regard, two major strategies have emerged, 
relying on direct or indirect means of inferring whether a 
fetal chromosomal anomaly is present.
Indirect approaches: cell-free mRNA or epigenetic differences
Cell-free DNA is present in the serum and plasma of all 
normal individuals. It is assumed to arise from dying or 
damaged cells, and may be a consequence of normal cell 
turnover.  Placentally  derived  cell-free  DNA  is  derived 
from turnover of the placental trophoblast tissue. The use 
of placentally derived cell-free fetal DNA has been shown 
to  be  useful  for  the  detection  of  fetal  loci  that  are 
completely absent from the maternal genome, such as the 
Y  chromosome  or  the  fetal  Rhesus  D  (RHD)  gene  in 
Rhesus  D  negative  mothers  [20,21].  The  situation  is, 
however, much more complex when studying fetal loci 
that are more similar to maternal ones because the few 
fetal cell-free DNA sequences present in maternal plasma 
are almost swamped by the preponderance of maternally 
derived ones. This renders the detection of fetal genetic 
loci  that  are  not  completely  absent  from  the  maternal 
genome difficult by current PCR-based approaches [22]. 
In  order  to  overcome  this  problem,  two  avenues  have 
been investigated: firstly, the use of placentally derived 
mRNA  species  not  expressed  by  maternal  tissues  [23]; 
and secondly, epigenetic differences between placentally 
and maternally derived cell-free DNA sequences [24].
The  hypothesis  behind  these  approaches  is  that  they 
should  theoretically  allow  an  absolute  discrimination 
between  fetal  and  maternal  cell-free  nucleic  acid 
sequences, and thus should not be influenced by an over-
whelming presence of maternal material. The analysis of 
the targeted fetal loci should then become as straight-
forward as that for the determination of fetal gender or 
Rhesus D status.
In  order  to  determine  chromosomal  ploidy,  the 
approaches rely on the quantitative assessment of hetero-
zygous single nucleotide polymorphism (SNP) loci in the 
nucleic acid sequences being interrogated [23,25,26]. If 
the fetus is euploid, the SNP ratio should be 1:1, whereas 
if it were aneuploid, the SNP ratio would be 1:2 or 2:1.
In the mRNA approach, mRNA transcripts from genes 
located on chromosomes 21 (Placenta specific-4, PLAC4) 
and 18 (serpin peptidase inhibitor clade b2, SERBINB2) 
have been examined [23,27]. In the first report on the 
detection  of  trisomy  21  using  PLAC4  mRNA  [23],  10 
affected  cases  could  be  distinguished  from  56  healthy 
cases with a sensitivity of 90% and a specificity of 96%. 
Unfortunately, almost 100 cases had to be excluded from 
analysis as they did not meet the necessary requirement 
for a heterozygous SNP locus in the PLAC4 mRNA. In a 
recent follow-up study [26], it has been suggested that 
the accuracy of this assay could be improved by the use of 
digital  PCR  rather  than  mass  spectrometry  for  the 
detection and quantification of the SNP alleles, as well as 
by quantitatively assessing cell-free PLAC4 mRNA levels. 
This study [26] was performed on only four cases with 
trisomy 21, however, and although the sensitivity reached 
100%, the specificity was only 89%.
In a study using SERBINB2 mRNA for the detection of 
trisomy  18,  three  out  of  four  samples  with  Edwards 
syndrome could be distinguished from healthy cases [27]. 
Unfortunately,  because  of  the  very  low  levels  of 
SERBINB2 mRNA in maternal plasma, the samples had 
to be pooled, thereby making a precise estimate of the 
usefulness of this approach difficult.
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differences between placental and maternal tissues could 
be used for fetal aneuploidy detection [28,29], the use of 
the MASPIN gene on chromosome 18 was explored. This 
gene has been shown to be hypomethylated in placental 
tissues  and  hypermethylated  in  maternal  blood  [28]. 
However, as it was not possible for the authors [28] to 
reliably distinguish cases with trisomy 18 from healthy 
controls when using pure placentally derived fetal genetic 
material,  it  is  unclear  whether  this  approach  will  be 
suitable for the analysis of cell-free DNA, for which the 
quantities of fetal material are considerably lower [28,29].
More recently, the epigenetic approach has been tested 
in a more complex manner using a combination of fetus-
specific  genetic  (ZFY  on  the  Y  chromosome)  and  epi-
genetic markers (holocarboxylase synthetase, HLCS, on 
chromo  some 21) [30]. Instead of relying on the analysis 
of SNP ratios, this new test relies on a comparison of the 
relative dosage of the HLCS and ZFY loci by digital PCR 
(see below for a technical description). In their exami-
nation, Tong and colleagues [30] were able to discrimi-
nate  5  cases  with  Down  syndrome  from  24  normal 
euploid cases.
Although  the  latter  results  seem  very  promising,  it  is 
important to realize that several conditions need to be met 
for these methods targeting fetus-specific sequences to be 
functional. These are: that there is an absolute distinction 
between the maternal and fetal  compart  ments; that the 
chromosomal  loci  being  examined  are  transcribed  at 
exactly the same rate, or are equally epigenetically altered; 
and for the HLCS and ZFY assay, that a reliable alternative 
to ZFY is obtained for gender-independent analysis. As 
such, considerable further improvement and multi-center 
large-scale studies will be necessary to reveal how valid 
these  conditions  are  and  whether  these  approaches  are 
suitable for clinical applications.
Direct approaches: digital PCR and next generation 
sequencing
Several  recent  studies  have,  however,  indicated  that  it 
may  be  possible  to  determine  fetal  ploidy  through  the 
direct analysis of cell-free DNA without having to resort 
to indirect means such as epigenetic markers or cell-free 
mRNA [31]. These findings are based on the development 
of new tools that enable a much more precise quantitative 
assessment of cell-free DNA sequences than was possible 
with techniques such as real-time PCR or PCR coupled 
with mass spectrometry.
In the first of these studies the technique of digital PCR 
[32]  was  used  for  the  quantification  of  fetal  DNA 
sequences  [11,33].  Digital  PCR  differs  from  other 
quantitative approaches, such as real-time PCR, which 
use the exponential phase of the PCR reaction, in that 
digital PCR allows the reaction to proceed to its plateau 
and then simply uses a ‘yes/no’ method to monitor the 
presence or absence of input template [34]. Because this 
method relies on the monitoring of numerous single PCR 
reactions,  it  required  the  development  of  microfluidic 
devices with several thousand reaction chambers in order 
for it to become viable [11,32,33].
By  these  means  two  independent  proof-of-principle 
studies [11,33] indicated that digital PCR could be used 
for  reliable  discrimination  between  aneuploid  and 
euploid cases on pure fetal genetic material, and that this 
may be possible when only 10% of the input template was 
of aneuploid origin, provided that 4,000 individual events 
were monitored [11,32,33]. As the concentration of cell-
free fetal DNA in maternal plasma is similar to 10%, this 
method may thus be useful for analyzing such samples 
[11,32,33].
The most spectacular evidence that the direct analysis 
of  cell-free  DNA  in  maternal  plasma  can  be  used  to 
detect fetal aneuploidy is provided by studies using ‘next 
generation’  or  ‘shotgun’  sequencing  [35-37].  In  this 
method,  very  short  fragments  from  the  entire  genome 
are amplified and sequenced [37]. In this manner some 
65,000 reads have been obtained for chromosome 21 and 
several million for the entire genome. However, instead 
of  using  these  sequence  data  for  genome  analysis,  the 
output data are examined in the same molecular counting 
manner as are digital PCR data. As the number of reads 
available is several orders of magnitude higher than what 
can  currently  be  attained  by  digital  PCR,  the  results 
would also be expected to be much more precise. This 
was  indeed  the  case  and,  in  both  studies,  all  cases  of 
aneuploidy could be reliably distinguished from euploid 
controls [35-37].
Development of new highly specific screening 
markers using proteomics
Protein biomarkers have formed the basis for fetal aneu-
ploidy screening tests for several decades, starting with 
the second trimester test that used maternal serum α-
fetoprotein, human chorionic gonadotrophin (hCG) and 
estriol [38]. This test, which was routinely used to screen 
pregnancies at 15 to 20 weeks of gestation, has largely 
been replaced by the first trimester combined test, which 
is performed at around 11 to 13 weeks of pregnancy [39]. 
This  test  uses  ultrasound  for  the  detection  of  nuchal 
translucency (related to the size of a fold in the skin at the 
base of the neck, which is increased in cases of Down 
syndrome) in combination with serum protein markers 
such  as  free  β-hCG  and  pregnancy-associated  plasma 
protein-A  (PAPP-A).  In  centers  with  skilled  ultrasono-
graphers, detection rates for pregnancies with a Down 
syndrome fetus of up to 80% can be attained. Unfortu-
nately,  both  tests  are  hampered  by  high  false  positive 
rates of the order of 5 to 8%, thereby leading to a large 
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performed  on  healthy  pregnancies.  One  way  in  which 
this problem has been proposed to be overcome is by the 
addition  of  more  placenta-specific  biomarkers,  and 
indeed,  slight  improvements  can  be  achieved  by  the 
addition  of  other  markers,  such  as  members  of  the 
inhibin/activin family [40].
Given that the placenta in Down syndrome has very 
characteristic  defects  in  trophoblast  differentiation,  it 
may  be  possible  that  associated  changes  in  protein 
expression are evident in the maternal plasma proteome 
[41]. For this reason several studies have used proteomic 
strategies to detect such potential biomarkers [38]. This 
approach  is,  however,  not  as  simple  as  it  would  seem 
because  of  the  incredible  complexity  of  the  plasma 
proteome, which contains peptides derived from every 
tissue  of  the  body.  Furthermore,  the  presence  of  very 
abundant  proteins,  such  as  serum  albumin  and 
immunoglobulin, effectively mask rare peptides, such as 
those  of  placental  origin.  An  additional  problem  that 
hampered many previous studies is that the tools used to 
measure quantitative differences in plasma peptide levels 
between  case  and  controls,  such  as  two-dimensional 
differential  in  gel  electrophoresis,  were  not  adequately 
sensitive and reliable.
This has largely been overcome by the development of 
techniques  such  as  the  isobaric  tag  for  relative  and 
absolute quantification (iTRAQ) method [42]. In a recent 
pilot study [43], we have examined whether this approach 
will be suitable for the development of Down syndrome 
screening markers. In our study [43] we examined first-
trimester plasma samples from mothers of fetuses with 
Down  syndrome  and  matched  healthy  controls,  which 
were labeled with quadruplex isobaric tags. Among the 
proteins found to be elevated in mothers of fetuses with 
Down syndrome, we were pleased to detect β-hCG, an 
important  component  of  current  screening  strategies, 
suggesting  that  the  iTRAQ  method  was  working.  Of 
particular interest was the detection of several molecules 
of the amyloid family associated with onset of senility in 
Alzheimer’s and Down syndrome patients.
The true power of proteomic analyses, especially when 
coupled with high-throughput quantitative analyses such 
as selective reaction monitoring, comes from the use of 
very  large  panels  (hundreds  to  thousands)  of  potential 
biomarkers [44]. Using such large panels it may be possible 
to minimize the effect of personal genomic differences.
Conclusions
Recent  developments  involving  technologies  such  as 
digital PCR or shotgun sequencing may bring about the 
long-awaited  dream  of  being  able  to  detect  fetal 
aneuploidies directly from a sample of maternal blood. 
The current problems hindering the immediate translation 
of  this  approach  into  the  clinic  are  the  cost  of  the 
instruments, the reagents and the experimental analysis, 
and the length of time taken to perform the subsequent 
bioinformatic analysis. This may, however, change as the 
next  generation  of  machines  becomes  available,  which 
will be priced at a fraction of the cost of current devices. 
Furthermore, by focusing on discrete targeted sequences 
(such  as  chromosomes  21,  18  and  13),  it  should  be 
possible  to  perform  smaller  analytic  runs  and  also  cut 
down  the  time  required  for  bioinformatic  analysis 
enormously.
Although it is unlikely that proteomic approaches will 
become so effective as to render them diagnostic, it is 
possible that the quantitative analysis of large panels of 
potential  biomarkers  by  mass  spectrometry-based 
techniques  such  as  selective  reaction  monitoring  may 
increase current screening sensitivity and specificity to a 
very high level.
The development of large panels of biomarkers, which 
take  into  account  personal  genomic  differences,  may 
increase the level of screening accuracy to such an extent 
that further testing, be it invasive or not, will be restricted 
to a well defined high risk group.
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